Ipratropiumbromid Hexal

Ipratropium bromide, the active ingredient in Ipratropiumbromid Hexal, is an anticholinergic presented as an inhalation product for inhalation use. It treats chronic obstructive pulmonary disease (COPD) and asthma in adult patients. GNH USA supplies Ipratropiumbromid Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is an anticholinergic bronchodilator used in obstructive airway diseases. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma: provides bronchodilation and helps control bronchospasm symptoms.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion causing throat discomfort. - Cough: irritation of the airway during inhalation. - Throat irritation: mild soreness after use. - Headache: transient pain often unrelated to dosage. - Dizziness: occasional light‑headed sensation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Angioedema: swelling of face, lips, or throat requiring urgent care. - Severe allergic reaction: anaphylaxis with rash, itching, or difficulty breathing. - Tachycardia: rapid heart rate that may be symptomatic. - Urinary retention: difficulty emptying the bladder, especially in predisposed individuals. - Vision changes: blurred vision or increased intra‑ocular pressure.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for anticholinergic effects. - Assess lung function: perform baseline spirometry to gauge severity. - Monitor anticholinergic signs: watch for dry mouth, urinary retention, or constipation. - Avoid in narrow‑angle glaucoma: risk of increased intra‑ocular pressure. - Use caution in the elderly: heightened sensitivity to anticholinergic load. - Do not combine with other anticholinergic inhalers without medical guidance. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, altering efficacy or increasing adverse effects.

Major Interactions (Avoid): - Concurrent anticholinergic agents: additive anticholinergic burden may exacerbate side effects. - Beta‑agonists: may mask signs of bronchospasm, complicating clinical assessment. - MAO inhibitors: potential for hypertensive episodes when combined.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of dry mouth and electrolyte imbalance. - Antihistamines: additive sedation or anticholinergic effects. - Theophylline: possible increase in respiratory side effects.